Menu
GeneBe

rs577852020

Variant summary

Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.

The NM_058216.3(RAD51C):c.1097G>A(p.Arg366Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00000682 in 1,613,026 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R366W) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.0000066 ( 0 hom., cov: 32)
Exomes 𝑓: 0.0000068 ( 0 hom. )

Consequence

RAD51C
NM_058216.3 missense

Scores

1
7
11

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:1U:7B:1

Conservation

PhyloP100: 3.83
Variant links:
Genes affected
RAD51C (HGNC:9820): (RAD51 paralog C) This gene is a member of the RAD51 family. RAD51 family members are highly similar to bacterial RecA and Saccharomyces cerevisiae Rad51 and are known to be involved in the homologous recombination and repair of DNA. This protein can interact with other RAD51 paralogs and is reported to be important for Holliday junction resolution. Mutations in this gene are associated with Fanconi anemia-like syndrome. This gene is one of four localized to a region of chromosome 17q23 where amplification occurs frequently in breast tumors. Overexpression of the four genes during amplification has been observed and suggests a possible role in tumor progression. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got 0 ACMG points.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect #exon/exons MANE UniProt
RAD51CNM_058216.3 linkuse as main transcriptc.1097G>A p.Arg366Gln missense_variant 9/9 ENST00000337432.9
LOC105371843XR_007065866.1 linkuse as main transcriptn.81-9763C>T intron_variant, non_coding_transcript_variant

Ensembl

Gene Transcript HGVSc HGVSp Effect #exon/exons TSL MANE Appris UniProt
RAD51CENST00000337432.9 linkuse as main transcriptc.1097G>A p.Arg366Gln missense_variant 9/91 NM_058216.3 P2O43502-1

Frequencies

GnomAD3 genomes
AF:
0.00000658
AC:
1
AN:
152050
Hom.:
0
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0000242
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.00
Gnomad OTH
AF:
0.00
GnomAD3 exomes
AF:
0.0000120
AC:
3
AN:
249618
Hom.:
0
AF XY:
0.00000742
AC XY:
1
AN XY:
134818
show subpopulations
Gnomad AFR exome
AF:
0.0000626
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.000100
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.00000685
AC:
10
AN:
1460858
Hom.:
0
Cov.:
31
AF XY:
0.00000688
AC XY:
5
AN XY:
726610
show subpopulations
Gnomad4 AFR exome
AF:
0.00
Gnomad4 AMR exome
AF:
0.0000224
Gnomad4 ASJ exome
AF:
0.0000384
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00000450
Gnomad4 OTH exome
AF:
0.0000497
GnomAD4 genome
AF:
0.00000657
AC:
1
AN:
152168
Hom.:
0
Cov.:
32
AF XY:
0.0000134
AC XY:
1
AN XY:
74424
show subpopulations
Gnomad4 AFR
AF:
0.0000241
Gnomad4 AMR
AF:
0.00
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.00
Gnomad4 OTH
AF:
0.00
Alfa
AF:
0.0000496
Hom.:
0
ExAC
AF:
0.0000165
AC:
2
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:7Benign:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingQuest Diagnostics Nichols Institute San Juan CapistranoSep 07, 2022The frequency of this variant in the general population, 0.000012 (3/249618 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant is described to be hypomorphic resulting in partial loss of function (PMID: 25292178 (2015), 22167183 (2012)). Additionally, the variant was reported in an individual with familial breast and/or ovarian cancer (PMID: 20400964 (2010)). Based on the available information, we are unable to determine the clinical significance of this variant. -
Uncertain significance, criteria provided, single submitterclinical testingGeneDxFeb 15, 2023Observed in at least one family with breast cancer and segregated with disease in two affected relatives; however, tumor analysis from one individual demonstrated no loss of heterozygosity (Meindl et al., 2010; Gevensleben et al., 2014); Published functional studies demonstrate reduced homologous recombination activity compared to wild-type, increased sensitivity to PARP inhibitors, and moderate sensitivity to DNA damaging agents, but no significant difference in RAD51 foci formation or interaction with RAD51B, RAD51D, XRCC2, or XRCC3 (Meindl et al., 2010; Somyajit et al., 2012; Somyajit et al., 2015; Mishra et al., 2018; Prakash et al., 2022); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25470109, 24993905, 25292178, 26740214, 20952512, 20400964, 14704354, 12966089, 36099300, 31567591, 29158291, 28829762, 34910513, 36562461, 22167183, 21537932) -
Hereditary cancer-predisposing syndrome Uncertain:2
Uncertain significance, criteria provided, single submitterclinical testingColor Diagnostics, LLC DBA Color HealthAug 23, 2023This missense variant replaces arginine with glutamine at codon 366 of the RAD51C protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Functional studies have reported conflicting findings for this variant for which some have reported hypomorphic or partial loss-of-function (PMID: 20400964, 22167183, 25292178), while others reported no impact on normal binding to RAD51 paralogs, sensitivity to cisplatin and Olaparib treatment and function in a homology-directed repair assay (PMID: 36099300, 37253112). This variant has been reported in several individuals affected with personal or family history of breast or ovarian cancer (PMID: 20400964, 23117857, 25470109). This variant also has been detected in a breast cancer case-control meta-analysis in 1/60466 cases and 2/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID RAD51C_000025). This variant has been identified in 3/249618 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Uncertain significance, criteria provided, single submitterclinical testingAmbry GeneticsMar 01, 2022The p.R366Q variant (also known as c.1097G>A), located in coding exon 9 of the RAD51C gene, results from a G to A substitution at nucleotide position 1097. The arginine at codon 366 is replaced by glutamine, an amino acid with highly similar properties. In a study of 1100 German high-risk breast and/or ovarian cancer families, this alteration was detected in one family (Meindl A et al. Nat. Genet., 2010 May;42:410-4). Another study detected this alteration in 1/492 breast cancer patients with family history of breast and/or ovarian cancer (Romero A et al. Breast Cancer Res. Treat., 2011 Oct;129:939-46). Functional studies have shown a reduction in homologous recombination activity from this alteration compared to wild-type protein (Somyajit K et al. Carcinogenesis, 2015 Jan;36:13-24). In another study, this alteration was shown to have reduced protein levels in the nucleus as compared to wild-type protein, but no change in protein levels in the mitochondria (Mishra A et al. Mol. Cell. Biol., 2018 02;38). This alteration was identified in a cohort of individuals with at least 3 primary melanoma diagnoses (Li C et al. Melanoma Res, 2020 06;30:247-251). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Uncertain:1Benign:1
Likely benign, no assertion criteria providedcurationLeiden Open Variation DatabaseNov 02, 2014Curator: Arleen D. Auerbach. Submitter to LOVD: Johan den Dunnen. -
Uncertain significance, criteria provided, single submitterclinical testingMendelicsMay 04, 2022- -
Ovarian cancer Pathogenic:1
Likely pathogenic, criteria provided, single submitterclinical testingLaboratory of Molecular Epidemiology of Birth Defects, West China Second University Hospital, Sichuan UniversityJan 01, 2022- -
Fanconi anemia complementation group O Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingInvitaeJan 28, 2024This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 366 of the RAD51C protein (p.Arg366Gln). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with breast cancer (PMID: 20400964). ClinVar contains an entry for this variant (Variation ID: 420041). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Experimental studies have shown that this missense change affects RAD51C function (PMID: 20400964, 22167183). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
Uncertain significance, criteria provided, single submitterclinical testingBaylor GeneticsJun 16, 2023- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.11
BayesDel_addAF
Uncertain
0.065
T
BayesDel_noAF
Benign
-0.14
Cadd
Uncertain
25
Dann
Pathogenic
1.0
DEOGEN2
Benign
0.14
T
Eigen
Uncertain
0.39
Eigen_PC
Uncertain
0.30
FATHMM_MKL
Uncertain
0.79
D
LIST_S2
Benign
0.84
T
M_CAP
Benign
0.015
T
MetaRNN
Uncertain
0.66
D
MetaSVM
Benign
-0.83
T
MutationAssessor
Uncertain
2.3
M
MutationTaster
Benign
0.74
D
PrimateAI
Benign
0.45
T
PROVEAN
Benign
-0.70
N
REVEL
Benign
0.22
Sift
Benign
0.031
D
Sift4G
Uncertain
0.037
D
Polyphen
1.0
D
Vest4
0.75
MutPred
0.21
Loss of loop (P = 0.0203);
MVP
0.83
MPC
0.29
ClinPred
0.29
T
GERP RS
3.1
Varity_R
0.047
gMVP
0.32

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs577852020; hg19: chr17-56811549; COSMIC: COSV104641817; COSMIC: COSV104641817; API